On this basis, the combination of FGFR3, TERT, and HRAS proto-oncogene mutations resulted in a sensitivity of 93% and a specificity of 89% for the diagnosis of bladder cancer, which shows that the combination of DNA methylation testing has great potential in the detection of bladder cancer. This evidence concerns the gene FGFR3 and urinary bladder cancer.